The DEA’s ongoing administrative review of broader marijuana rescheduling from Schedule I to Schedule III under the Controlled Substances Act faces a procedural pause following a September 29, 2026 stay order by Chief Administrative Law Judge Derek Julius. Opponents cited a new Government Accountability Office report questioning DEA and FDA documentation of scheduling procedures, prompting motions to supplement the record after July hearings concluded on the proposal to cover all cannabis products. A partial April 2026 final rule already moved FDA-approved and state-licensed medical marijuana to Schedule III, while recreational products remain Schedule I. Government responses to the latest motions are due in mid-to-late October 2026, after which the ALJ may issue a recommendation subject to DEA administrator review and exceptions. Trader pricing reflects uncertainty over the timeline for any further agency action.